N-Methylaspartate (NMDA)

Subscribe to Selected New Research on N-Methylaspartate

5536 relevant articles (349 outcomes, 823 trials/studies) found for this Bio-Agent

Description: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).

Also Known As:

NMDA; N Methyl D aspartate; N-Methyl-D-aspartic Acid; Acid, N-Methyl-D-aspartic; N Methyl D aspartic Acid; N Methylaspartate; N-Methyl-D-aspartate; D-Aspartic acid, N-methyl-

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Amino Acids: 8523

Acidic Amino Acids: 33

Aspartic Acid: 1872

N-Methylaspartate: 5536

N-methyl-DL-aspartic acid: 11

2-methylaspartic acid

Dicarboxylic Amino Acids: 20

Aspartic Acid: 1872

N-Methylaspartate: 5536

N-methyl-DL-aspartic acid: 11

2-methylaspartic acid

Experts

1.	Raymond, Lynn A: 8 articles (12/2007 - 03/2002)
2.	Zhang, Guang-Yi: 8 articles (01/2007 - 05/2003)
3.	Meador-Woodruff, James H: 6 articles (08/2008 - 06/2003)
4.	Hayden, Michael R: 6 articles (12/2007 - 03/2002)
5.	Krystal, John H: 6 articles (04/2007 - 07/2002)
6.	Armstead, William M: 6 articles (05/2005 - 08/2002)
7.	Zhang, Guangyi: 6 articles (01/2004 - 04/2002)
8.	Mishina, Masayoshi: 5 articles (08/2008 - 06/2002)
9.	Fernandes, Herman B: 5 articles (12/2007 - 04/2003)
10.	Zhang, Quan-Guang: 5 articles (01/2007 - 01/2004)

Related Diseases

1.	Seizures (Seizure) 04/08/2002 - "NMDA antagonists derived from 5-phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione (3a) are potent anticonvulsant agents, and display strong protective effects in the electroshock-induced convulsion assay in mice" 11/16/1993 - "Prior administration of CPA resulted either in a delay of seizure onset and unchanged mortality (0.5 mg/kg CPA, 60 mg/kg NMDA) or in elimination of tonic episodes and a significant reduction in postictal mortality (1, 2 mg/kg CPA; 60, 125 mg/kg NMDA)" 04/01/1990 - "We report experiments performed to determine if NMDA receptor antagonists are effective in stopping seizures in the late stages of SE" 09/25/2008 - "Here, we evaluated the protective efficacy of [+]-Hup A for NMDA-induced seizure in a rat model" 02/01/1998 - "Protective effects of neurosteroids against NMDA-induced seizures and lethality in mice." Get all the results and reference details, order at left...
2.	Pain (Aches) 10/01/2003 - "Among NMDA receptor subtypes, the NR2B subunit-containing receptors appear particularly important for nociception, thus leading to the possibility that NR2B-selective antagonists may be useful in the treatment of chronic pain." 03/01/2006 - "We conclude that adjuvant chronic pain treatment with N-methyl-d-aspartate receptor antagonists might be beneficial for chronic pain if enhanced sensitization is involved and that the quantitative sensory test of temporal summation may be used to verify this." 01/01/2000 - "Thus, provided their therapeutic ratio is favorable, NMDA-receptor antagonists may be effective in the treatment of some types of chronic pain." 08/01/1995 - "We conclude that NMDA antagonists may have promise for the treatment of neuropathic pain, but strategies are needed to improve their therapeutic ratio, such as intrathecal administration or systemic treatment with more selective drugs." 01/01/2008 - "NMDA antagonists may be effective in many neuropathic pain states" Get all the results and reference details, order at left...
3.	Ischemia 08/01/1991 - "We conclude that systemically administered noncompetitive NMDA receptor antagonists do not provide a marked protection against neuronal damage after a transient period of severe forebrain ischemia." 12/01/1992 - "Recent therapeutic studies have demonstrated the efficacy of non-NMDA receptor antagonists in experimental studies of global ischemia." 12/01/1997 - "-(S)-Alpha-phenyl-2-pyridine-ethanamine Dihydrochloride-, a low affinity uncompetitive N-methyl-D-aspartic acid antagonist, is effective in rodent models of global and focal ischemia." 06/01/2008 - "NMDA receptor blocker ameliorates ischemia-reperfusion-induced renal dysfunction in rat kidneys." 06/01/2005 - "Increased extracellular K+ concentration reduces the efficacy of N-methyl-D-aspartate receptor antagonists to block spreading depression-like depolarizations and spreading ischemia." Get all the results and reference details, order at left...
4.	Schizophrenia (Dementia Praecox) 02/01/2004 - "Overall, the findings indicate that agents which potentiate NMDA transmission may be therapeutically beneficial in treatment of persistent symptoms of schizophrenia." 01/01/2006 - "According to the NMDA receptor hypofunction hypothesis, any treatment that enhances NMDA receptor activity may prove useful for the treatment of the complex symptoms that define schizophrenia" 02/01/2008 - "N-methyl-D-aspartate receptor (NMDAR) hypo-function theory of schizophrenia proposes that impairment in NMDAR function be associated with the pathophysiology of schizophrenia and suggests that enhancement of the receptor function may produce efficacy for schizophrenia" 09/01/2008 - "The administration of these drugs in animals has been used as a pharmacological model to study the NMDA receptor hypofunction-hypothesis of schizophrenia" 09/01/2008 - "Many studies in recent years suggest that schizophrenia is a synaptic disease that crucially involves a hypofunction of N-methyl-D-aspartate receptor-mediated signaling" Get all the results and reference details, order at left...
5.	Brain Ischemia (Cerebral Ischemia) 01/01/1990 - "In summary, 8319 is a noncompetitive NMDA antagonist with good anticonvulsant activity and may possess neuroprotective properties useful in the treatment of brain ischemia." 11/01/1990 - "These data suggest that blockade of the N-methyl-D-aspartate receptor is effective in reducing the infarct size after focal cerebral ischemia" 07/01/1993 - "Characterization of the cerebroprotective efficacy of the competitive NMDA receptor antagonist CGP40116 in a rat model of focal cerebral ischemia: an in vivo magnetic resonance imaging study." 01/01/1993 - "In the clinical management of cerebral ischemia not only the intrinsic neuronal degenerative process, but also the deteriorating extracellular milieu, needs to be treated, and the latter may not be improved by NMDA receptor blockade.(ABSTRACT TRUNCATED AT 400 WORDS)" 02/01/2006 - "The present study examined the neuroprotection of three chloride blockers in an in vitro cell model of cerebral ischemia established by treatment of cultured rat hippocampal neurons with NMDA" Get all the results and reference details, order at left...
422 Diseases and 5536 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	N-Methylaspartate (NMDA)
2.	Dizocilpine Maleate (Dizocilpine)
3.	Memantine (Namenda)
4.	Glycine (Aminoacetic Acid)
5.	Ketamine
6.	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
7.	Glutamic Acid (Glutamate)
8.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
9.	Kainic Acid (Kainate)
10.	Dextromethorphan (Levomethorphan)
1334 Drugs and Important Bio-Agents and 4601 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Analgesia
2.	Drug Therapy (Chemotherapy)
3.	Premedication
4.	Therapeutics
5.	Ligation
37 Therapies and Procedures and 147 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>